ChiCTR‐IPR‐17010811.
| Methods |
Type of trial: efficacy trial Allocation: randomised Intervention model: parallel assignment Masking: — Primary purpose: treatment |
| Participants |
Condition: T2DM Enrollment: estimated 24 participants of interest to this review Inclusion criteria: age between 30 and 75 years, T2DM, hyperglucagonaemia, oral hypoglycemic drugs, the general HbA1c <= 10%, the entire study period does not adjust the amount of antidiabetic drug usage. Exclusion criteria: poor blood pressure control: SBP > 180 mmHg, DBP > 100 mmHg, other diseases affecting the metabolism of glycolipid: hyperthyroidism, hypothyroidism, Cushing's syndrome, heart failure (NYHA classification: III ‐ IV), ALT and / or AST > 3 times ULN, or active liver disease, PLT < 60 * 10^9/L, Hb < 100 g/L, chronic renal disease or severe renal impairment, definition of serum creatinine > 135 mmol/L (1.5 mg/dL (male), and 110 mmol/L (1.3 mg/dL) (female), 2 years had malignant tumors, patients with bleeding tendency, recent gastrointestinal bleeding, anticoagulant therapy, have been pregnant or plan to be pregnant in the near future, known to metformin, aspirin drug allergy, 30 days participated in other drug clinical trials, there are other circumstances that can not participate in the intervention of the followers, the investigators considered the participants to be affected by the outcome of the assessment of the disease or not suitable for inclusion. |
| Interventions |
Intervention(s): metformin Comparator(s): placebo |
| Outcomes |
Primary outcome(s): blood parameters Secondary outcome(s): — Other outcome(s): — |
| Study details | Trial identifier: ChiCTR-IPR-17010811 |
| Publication details |
Language of protocol: Chinese / English Funding: non‐commercial (university) Publicationstatus: unclear if published |
| Stated aim of study | Quote: "To determine the hypothesis whether hyperglucagonaemia causes metformin resistance and aspirin is able to improve metformin resistance as observed in our animal experiment." |
| Notes | Only the protocol is available. Marked as a study awaiting classification due to a lack of data to assess inclusion. Trial authors have been contacted. |